Inhalation Sciences and RISE collaborate successfully on first proposal for global project on antibiotic resistance
(Stockholm, 9 June 2022) Inhalation Sciences (ISAB) and RISE Research Institutes of Sweden have collaborated successfully on a first proposal to a major global project into antibiotic resistance and inhaled antibiotics. RISE is an ISAB customer and a leading player within Sweden promoting collaborative research between academia, industry and the public sector.
The research project, APRINHA, is being carried out by JPIAMR (the Joint Programming Initiative on Antimicrobial Resistance). It will explore the strong potential of inhaled antibiotics to help reduce antibiotic resistance – an urgent issue for researchers as antibiotic resistance has surged during the COVID-19 pandemic due to a dramatic increase in the use of antibiotics to treat pulmonary complications, co-infections and secondary infections.
The first proposal that ISAB and RISE submitted, as part of a wider consortium, has been invited to proceed to the next level. It received encouraging feedback from JPIAMR’s scientific review panel: “The project is well-written; the consortium has all the expertise to achieve the goals of the project... one of the strengths of the project is that it has potential for other multiresistant bacteria, with approaches that can be translated for other infectious models.”
The consortium must now submit a full proposal by July 5. ISAB’s pre-clinical in vivo technology will play an important role. Its unique one-animal-at-a-time technology enables the individual control of inhaled doses of aerosol and delivers high-precisians results with a standard deviation of <10%.
Ian Cotgreave, Vice President of the Department for Chemical and Pharmaceutical Safety, RISE: “We have had very positive experience with PreciseInhale, our ISAB aerosol system, and we welcome the expertise in aerosol delivery and PK studies that the ISAB team will combine with ours as we move forward.”
Manoush Masarrat, CEO ISAB: “This is an international project with applications from top research organizations and consortia worldwide. We are very pleased to be partnering together with RISE, an important partner in inhalation drug development, at this level.”
For more information on Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.